Ballentine Partners LLC lifted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 13.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,120 shares of the company’s stock after purchasing an additional 4,725 shares during the period. Ballentine Partners LLC’s holdings in Johnson & Johnson were worth $7,264,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Lincoln Capital Corp increased its stake in Johnson & Johnson by 15.9% in the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after buying an additional 183 shares in the last quarter. Ieq Capital LLC grew its position in shares of Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after purchasing an additional 6,154 shares in the last quarter. RFG Advisory LLC grew its position in shares of Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after purchasing an additional 594 shares in the last quarter. Willis Investment Counsel grew its position in shares of Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after purchasing an additional 1,358 shares in the last quarter. Finally, FDx Advisors Inc. grew its position in shares of Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after purchasing an additional 153 shares in the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. Johnson & Johnson’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period last year, the business earned $2.13 EPS. On average, research analysts predict that Johnson & Johnson will post 10.49 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on JNJ. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Atlantic Securities raised their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 25th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $180.00 to $179.00 and set an “equal weight” rating for the company in a research note on Monday, April 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 1st. Finally, Piper Sandler cut their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $173.07.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 4/10 – 4/14
- What is an IRA Account? All About IRAs
- Investing in Quantum Computing: A Guide
- Earnings Beat Proves Citigroup to be The Cheaper Bank Stock
- How to Invest in an IRA in 7 Simple Steps
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
